Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

Anti-CD3 mAb

Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval

OTHER

Diabetes Standard of Care Treatment

Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.

DIETARY_SUPPLEMENT

Iron supplementation

Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.

Trial Locations (7)

10032

Dept. of Medicine, Division of Endocrinology and the Naomi Berrie Diabetes Center/Columbia University, New York

30912

Medical College of Georgia, Augusta

80262

Barbara Davis Center for Childhood Diabetes, Denver

94143

The Diabetes Center at UCSF, San Francisco

98108

Benaroya Research Institute, Seattle

98122

Pacific Northwest Research Institute/University of Washington, Seattle

06520

Yale University, New Haven

All Listed Sponsors
collaborator

Immune Tolerance Network (ITN)

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00129259 - Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes | Biotech Hunter | Biotech Hunter